| 2025-04-22 | +0.43 % |
|
| 2025-04-21 | -3.15 % |
|
| 2025-04-17 | -1.84 % |
|
| 2025-04-15 | -0.4 % |
|
| 2025-04-11 | +0.78 % |
|
| 2025-04-10 | -1.72 % |
|
| 2025-04-08 | +5.92 % |
|
| 2025-04-07 | +0.3 % |
|
| 2025-04-04 | -5.7 % |
|
| 2025-04-01 | +0.34 % |
|
| 2025-03-31 | +0.91 % |
|
| 2025-03-26 | +1.08 % |
|
| 2025-03-25 | -1.61 % |
|
| 2025-03-24 | +0.78 % |
|
| 2025-03-20 | +1.07 % |
|
| 2025-03-18 | +1.38 % |
|
| 2025-03-17 | +1.48 % |
|
| 2025-03-13 | +1.4 % |
|
| 2025-03-07 | +1.66 % |
|
| 2025-03-06 | -1.06 % |
- CVS Health (CVS) stock fell by -1.06% amidst a broader market downturn influenced by rising tariffs and trade disputes, leading investors to be cautious about stocks in sectors vulnerable to economic shifts and potential trade wars.
The decrease in CVS Health's stock can be attributed to general market concerns over trade policies, which have sparked fears of inflation and slowed economic growth, thereby affecting investor confidence in equities, including those in the healthcare sector.
- CVS Health (CVS) stock fell by 1.06% due to ongoing competition and challenges in the retail pharmacy sector, particularly in light of Walgreens' recent announcement to go private after struggling financially.
- CVS Health (CVS) stock declined by 1.06% in response to Walgreens Boots Alliance's announcement of a buyout agreement with Sycamore Partners, highlighting increased competition and the declining valuation of traditional drugstore chains amid market shifts.
- CVS Health (CVS) stock experienced a decline of 1.06% due to competitive pressures from Walgreens, which is transitioning to a private company amid significant challenges in the retail pharmacy market, highlighting industry volatility that could impact CVS's performance as well.
- CVS Health (CVS) stock declined by -1.06% as the market reacts to Walgreens Boots Alliance's impending $10 billion acquisition by Sycamore Partners, which raises concerns about competition and the future viability of retail pharmacy models.
The drop in CVS stock can be attributed to investor sentiment stemming from the challenges faced by Walgreens, including significant financial losses and store closures, which may indicate broader issues within the retail pharmacy sector that could affect CVS as well.
|
| 2025-03-04 | -1.06 % |
|
| 2025-02-20 | -1.97 % |
|
| 2025-02-19 | +1.27 % |
|
| 2025-02-18 | -0.39 % |
|
| 2025-02-14 | -0.81 % |
|
| 2025-02-13 | +4.98 % |
|
| 2025-02-12 | +14.95 % |
- CVS Health's stock surged 14.95% after the company reported fourth-quarter results that exceeded expectations and provided optimistic guidance for 2025.
- CVS Health (CVS) stock surged by 14.95% following the company's quarterly earnings report, which exceeded Wall Street's expectations despite a slight decline in its healthcare benefits segment, as its healthcare services and retail pharmaceutical operations showed improvements.
- CVS Health's stock surged 14.95% following the release of stronger-than-expected fourth quarter earnings and an improved benefit-expense ratio.
- CVS Health (CVS) stock surged 14.95% following the company's fourth quarter and full-year earnings report for 2024, which exceeded Wall Street expectations with a full-year revenue of $372.8 billion and a fourth quarter revenue of $97.7 billion.
The stock's rise is attributed to better-than-expected earnings, improved medical loss ratio figures, and positive growth in its retail pharmaceutical and healthcare services segments, despite ongoing challenges in the healthcare benefits area.
- CVS Health's stock surged by 14.95% following the company's fourth-quarter earnings report, which exceeded Wall Street expectations for revenue and profits, despite challenges in its insurance segment, as well as a positive full-year earnings outlook that aligned with analyst forecasts. The increase in stock price can be attributed to better-than-expected performance across CVS's business segments, as well as management's plans for cost cuts and improvements in future Medicare Advantage margins.
|
| 2025-02-11 | +1.31 % |
|
| 2025-02-07 | -0.42 % |
|
| 2025-02-06 | -2.6 % |
|
| 2025-02-05 | -1.17 % |
|
| 2025-02-04 | +0.71 % |
|
| 2025-02-03 | -0.94 % |
|
| 2025-01-30 | -0.14 % |
- CVS Health (CVS) stock declined by 0.14% after Leerink Partners lowered their FY2024 earnings per share estimates for the company from $5.21 to $5.16, contributing to investor concerns regarding its profitability outlook.
- CVS Health's (CVS) stock declined by 0.14% as institutional investors exhibited mixed investment behaviors, with Geneos Wealth Management substantially reducing its stake, indicating potential volatility or uncertainty in the company's outlook.
- CVS Health (CVS) stock experienced a slight decline of -0.14% amid a broader trend of significant retail store closures in the U.S., driven by inflation, a shift towards online shopping, and changing consumer preferences, which negatively impact brick-and-mortar retail performance.
- CVS Health (CVS) stock decreased by 0.14% despite recent positive ratings and price target increases from several brokerages, likely due to lower trading volume and market sentiment rather than specific negative news about the company.
- CVS Health's stock decreased by 0.14%, impacted by varied adjustments in institutional holdings and mixed sentiment from analysts, despite reporting a slight earnings beat and increased year-over-year revenues.
|
| 2025-01-27 | +3.02 % |
|
| 2025-01-24 | +1.36 % |
|
| 2025-01-23 | +1.57 % |
|
| 2025-01-22 | -0.3 % |
|
| 2025-01-21 | +1.01 % |
|
| 2025-01-17 | +1.27 % |
|
| 2025-01-16 | -0.35 % |
|
| 2025-01-15 | +1.11 % |
|
| 2025-01-14 | +0.1 % |
|
| 2025-01-13 | +7.31 % |
|
| 2025-01-10 | +4.35 % |
|
| 2025-01-07 | -0.09 % |
|
| 2025-01-06 | +0.11 % |
|
| 2025-01-03 | +3.51 % |
|
| 2025-01-02 | -1.49 % |
|
| 2024-12-31 | +2.16 % |
|
| 2024-12-26 | +1.51 % |
|
| 2024-12-24 | +0.25 % |
|
| 2024-12-23 | -0.5 % |
|
| 2024-12-19 | -3.31 % |
|
| 2024-12-17 | -5.49 % |
|
| 2024-12-16 | -5.61 % |
|
| 2024-12-13 | -0.42 % |
|
| 2024-12-12 | -4.21 % |
|
| 2024-12-10 | -1.64 % |
|
| 2024-12-06 | -2.76 % |
|
| 2024-12-05 | -2.05 % |
|
| 2024-12-04 | -1.93 % |
|
| 2024-12-02 | -1.29 % |
|
| 2024-11-26 | -1.78 % |
|
| 2024-11-25 | +3.57 % |
|
| 2024-11-22 | +1.59 % |
|
| 2024-11-21 | +0.48 % |
|
| 2024-11-20 | +1.9 % |
- CVS Health (CVS) stock rose by 1.9%, driven by unusually high options trading volume and positive quarterly earnings that exceeded estimates, alongside supportive movements from institutional investors and analysts raising target prices.
- CVS Health (CVS) stock rose by 1.9% due to positive analyst reports increasing their target prices and ratings, along with strong quarterly earnings that exceeded expectations, contributing to a favorable market sentiment around the stock.
- The article discusses Dr. Mehmet Oz's nomination to lead the Centers for Medicare & Medicaid Services, highlighting potential conflicts of interest due to his significant investments in healthcare stocks, including CVS Health (CVS), which may have contributed to CVS's stock price increase of 1.9% as investors anticipate favorable healthcare policies under his leadership.
- CVS Health (CVS) stock rose by 1.9% likely due to investor optimism surrounding the potential expansion of private Medicare Advantage plans, which are expected to benefit companies like CVS as they align with proposals by influential figures such as Dr. Mehmet Oz, who owns CVS stock and advocates for such healthcare reforms.
- CVS Health's stock rose 1.9% amid mixed analyst reports, with some firms raising their price targets and outlooks on the stock while others reduced earnings estimates, reflecting overall investor optimism and strong quarterly earnings that beat expectations.
|
| 2024-11-19 | -0.5 % |
|
| 2024-11-18 | +5.38 % |
|
| 2024-11-14 | +1.51 % |
|
| 2024-11-13 | +0.44 % |
|
| 2024-11-11 | +0.49 % |
|
| 2024-11-07 | -7.37 % |
|
| 2024-11-06 | +11.33 % |
|
| 2024-11-01 | -1.15 % |
|
| 2024-10-30 | +0.25 % |
|
| 2024-10-29 | -1.94 % |
|
| 2024-10-28 | +1.54 % |
- CVS Health (CVS) stock rose by 1.54% following DekaBank Deutsche Girozentrale's substantial 222.9% increase in its stake in the company during the third quarter, signaling strong investor confidence.
- CVS Health's stock rose by 1.54% due to increased institutional investor confidence, with several firms boosting their holdings and analysts maintaining positive ratings and price targets for the company's shares.
- CVS Health's stock rose by 1.54% due to positive analyst ratings and target price adjustments, despite a recent target price decrease by Mizuho, as other firms increased their price targets or maintained "buy" ratings, indicating strong investor interest and confidence in the company's performance.
- CVS Health (CVS) stock rose by 1.54% last night, likely driven by significant institutional investment increases, positive quarterly earnings that beat analysts' expectations, and a recently announced quarterly dividend that contributes to overall investor confidence and interest in the company's shares.
- CVS Health (CVS) stock rose 1.54% due to significant institutional investment interest, including a massive stake increase by Pathway Financial Advisers, alongside positive earnings performance and analyst upgrades, indicating strong market confidence.
|
| 2024-10-25 | +0.66 % |
|
| 2024-10-24 | -1.16 % |
|
| 2024-10-23 | -0.12 % |
|
